Sonia Lain

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Sonia Lain letar efter molekyler som kan utvecklas till framtida cancerbehandlingar. Ur mer än 60 000 substanser har hon valt ut de mest lovande kandidaterna. Efter att de molekylära mekanismerna kartlagts går det också att se vilka andra sjukdomar som substanserna kan vara effektiva mot.

Artiklar

Article: HELIYON. 2024;10(1):e23831
Retinoblastoma vulnerability to combined de novo and salvage pyrimidine ribonucleotide synthesis pharmacologic blockage
Mollick T; Darekar S; Dalarun B; Plastino F; Zhang J; Fernandez AP; Alkasalias T; Andre H; Lain S
Article: BIOESSAYS. 2022;44(12):e2200128
Asymmetric inheritance of cytoophidia could contribute to determine cell fate and plasticity The onset of alternative differentiation patterns in daughter cells may rely on the acquisition of either CTPS or IMPDH cytoophidia
Darekar S; Lain S
Article: CELL DEATH DISCOVERY. 2022;8(1):464
Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells
Alkasalias T; Zhang J; Madapura H; Dalarun B; Reina OB; Lewensohn R; Viktorsson K; Salihi A; Darekar S; Lain S
Article: ISCIENCE. 2021;24(5):102494
DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance
Zhang J; Teran G; Popa M; Madapura H; Ladds MJGW; Lianoudaki D; Grunler J; Arsenian-Henriksson M; McCormack E; Rottenberg ME; Catrina S-B; Lain S; Darekar S
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2020;295(52):17935-17949
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology
Ladds MJGW; Popova G; Pastor-Fernandez A; Kannan S; van Leeuwen IMM; Hakansson M; Walse B; Tholander F; Bhatia R; Verma CS; Lane DP; Lain S
Article: FEBS JOURNAL. 2020;287(13):2823-2833
High intracellular stability of the spidroin N-terminal domain in spite of abundant amyloidogenic segments revealed by in-cell hydrogen/deuterium exchange mass spectrometry
Kaldmae M; Leppert A; Chen G; Sarr M; Sahin C; Nordling K; Kronqvist N; Gonzalvo-Ulla M; Fritz N; Abelein A; Lain S; Biverstal H; Jornvall H; Lane DP; Rising A; Johansson J; Landreh M
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2020;63(8):3915-3934
Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability
Popova G; Ladds MJGW; Johansson L; Saleh A; Larsson J; Sandberg L; Sahlberg SH; Qian W; Gullberg H; Garg N; Gustavsson A-L; Haraldsson M; Lane D; Yngve U; Lain S
Article: CLINICAL GENETICS. 2019;96(3):216-225
Functional characterization of novel germline TP53 variants in Swedish families
Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Bohm S; Lain S; Borg A; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
Article: JOURNAL OF CLINICAL INVESTIGATION. 2018;128(9):4115-4131
Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive
Keszei M; Record J; Kritikou JS; Wurzer H; Geyer C; Thiemann M; Drescher P; Brauner H; Kocher L; James J; He M; Baptista MAP; Dahlberg CIM; Biswas A; Lain S; Lane DP; Song W; Putsep K; Vandenberghe P; Snapper SB; Westerberg LS
Article: JOURNAL OF PHYSICAL CHEMISTRY LETTERS. 2018;9(14):4082-4086
Mass Spectrometry Reveals the Direct Action of a Chemical Chaperone
Gault J; Lianoudaki D; Kaldmae M; Kronqvist N; Rising A; Johansson J; Lohkamp B; Lain S; Allison TM; Lane DP; Marklund EG; Landreh M
Article: NATURE COMMUNICATIONS. 2018;9(1):1107
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Fernandez AP; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Farnegardh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Hakansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Lain S
Article: CELL CHEMICAL BIOLOGY. 2018;25(3):309-317.e4
Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase
Costeira-Paulo J; Gault J; Popova G; Ladds MJGW; van Leeuwen IMM; Sarr M; Olsson A; Lane DP; Lain S; Marklund EG; Landreh M
Article: PLOS ONE. 2018;13(4):e0195956
Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib
Ladds MJGW; Pastor-Fernandez A; Popova G; van Leeuwen IMM; Eng KE; Drummond CJ; Johansson L; Svensson R; Westwood NJ; McCarthy AR; Tholander F; Popa M; Lane DP; McCormack E; McInerney GM; Bhatia R; Lain S
Article: CELL CYCLE. 2016;15(9):1267-1275
cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response
Madapura HS; Salamon D; Wiman KG; Lain S; Klein E; Nagy N
Article: ONCOTARGET. 2015;6(18):16488-16506
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells
Sachweh MCC; Stafford WC; Drummond CJ; McCarthy AR; Higgins M; Campbell J; Brodin B; Arner ESJ; Lain S
Article: NATURE BIOTECHNOLOGY. 2015;33(4):415-423
Acetylation site specificities of lysine deacetylase inhibitors in human cells
Scholz C; Weinert BT; Wagner SA; Beli P; Miyake Y; Qi J; Jensen LJ; Streicher W; McCarthy AR; Westwood NJ; Lain S; Cox J; Matthias P; Mann M; Bradner JE; Choudhary C
Article: CELL DEATH & DISEASE. 2014;5(10):e1483
SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth
Ma L; Maruwge W; Strambi A; D'Arcy P; Pellegrini P; Kis L; de Milito A; Lain S; Brodin B
Article: CELL STEM CELL. 2014;15(4):431-446
SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells
Li L; Osdal T; Ho Y; Chun S; McDonald T; Agarwal P; Lin A; Chu S; Qi J; Li L; Hsieh Y-T; Dos Santos C; Yuan H; Ha T-Q; Popa M; Hovland R; Bruserud O; Gjertsen BT; Kuo Y-H; Chen W; Lain S; McCormack E; Bhatia R
Article: MOLECULAR CANCER. 2014;13:116
Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
Haaland I; Opsahl JA; Berven FS; Reikvam H; Fredly HK; Haugse R; Thiede B; McCormack E; Lain S; Bruserud O; Gjertsen BT
Article: MOLECULAR CANCER THERAPEUTICS. 2013;12(4):471-480
Modulation of p53 C-Terminal Acetylation by mdm2, p14^ARF, and Cytoplasmic SirT2
van Leeuwen IMM; Higgins M; Campbell J; McCarthy AR; Sachweh MCC; Navarro AM; Lain S
Article: MOLECULAR CANCER THERAPEUTICS. 2013;12(4):352-360
Tenovin-D3, a Novel Small-Molecule Inhibitor of Sirtuin SirT2, Increases p21 (CDKN1A) Expression in a p53-Independent Manner
McCarthy AR; Sachweh MCC; Higgins M; Campbell J; Drummond CJ; van Leeuwen IMM; Pirrie L; Ladds MJGW; Westwood NJ; Lain S
Article: CELL DEATH & DISEASE. 2013;4(3):e533
Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression
Sachweh MCC; Drummond CJ; Higgins M; Campbell J; Lain S
Article: SCIENTIFIC REPORTS. 2013;3:1275
Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6
MacCallum SF; Groves MJ; James J; Murray K; Appleyard V; Prescott AR; Drbal AA; Nicolaou A; Cunningham J; Haydock S; Ganley IG; Westwood NJ; Coates PJ; Lain S; Tauro S
Article: CELL CYCLE. 2012;11(24):4563-4569
p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP
Madapura HS; Salamon D; Wiman KG; Lain S; Klein G; Klein E; Nagy N
Article: CELL CYCLE. 2012;11(9):1851-1861
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells
van Leeuwen IMM; Rao B; Sachweh MCC; Lain S
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2012;20(5):1779-1793
Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins
McCarthy AR; Pirrie L; Hollick JJ; Ronseaux S; Campbell J; Higgins M; Staples OD; Fanny T; Slawin AMZ; Lain S; Westwood NJ
Article: CELL CYCLE. 2011;10(10):1590-1598
Mechanism-specific signatures for small-molecule p53 activators
van Leeuwen IMM; Higgins M; Campbell J; Brown CJ; McCarthy AR; Pirrie L; Westwood NJ; Lain S
Article: RSC MEDICINAL CHEMISTRY. 2011;2(7):611-615
N1-Benzyl substituted cambinol analogues as isozyme selective inhibitors of the sirtuin family of protein deacetylases
Medda F; Joseph TL; Pirrie L; Higgins M; Slawin AMZ; Lain S; Verma C; Westwood NJ
Article: ONCOTARGET. 2010;1(7):639-650
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy
Rao B; van Leeuwen IMM; Higgins M; Campbell J; Thompson AM; Lane DP; Lain S
Article: COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY. 2010;2(9):a001222
p53-based Cancer Therapy
Lane DP; Cheok CF; Lain S
Article: DNA REPAIR. 2009;8(10):1215-1224
Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain
Yadavilli S; Mayo LD; Higgins M; Lain S; Hegde V; Deutsch WA
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2009;35(3):649-656
Leptomycin B induces apoptosis in cells containing the whole HPV 16 genome
Jolly CE; Gray LJ; Parish JL; Lain S; Herrington CS
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2009;52(9):2673-2682
Novel Cambinol Analogs as Sirtuin Inhibitors: Synthesis, Biological Evaluation, and Rationalization of Activity
Medda F; Russell RJM; Higgins M; McCarthy AR; Campbell J; Slawin AMZ; Lane DP; Lain S; Westwood NJ
Article: CELL CYCLE. 2008;7(21):3417-3427
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen
Staples OD; Hollick JJ; Campbell J; Higgins M; McCarthy AR; Appleyard V; Murray KE; Baker L; Thompson A; Ronseaux S; Slawin AMZ; Lane DP; Westwood NJ; Lain S
Article: CANCER CELL. 2008;13(5):454-463
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator
Lain S; Hollick JJ; Campbell J; Staples OD; Higgins M; Aoubala M; McCarthy A; Appleyard V; Murray KE; Baker L; Thompson A; Mathers J; Holland SJ; Stark MJR; Pass G; Woods J; Lane DP; Westwood NJ
Article: ONCOGENE. 2007;26(28):4059-4070
Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6
Camus S; Menendez S; Cheok CF; Stevenson LF; Lain S; Lane DP
Article: INTERNATIONAL JOURNAL OF CANCER. 2007;120(11):2317-2324
Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes
Gray LJ; Bjelogrlic P; Appleyard VCL; Thompson AM; Jolly CE; Lain S; Herrington CS
Article: INTERNATIONAL JOURNAL OF CANCER. 2005;115(5):701-710
Pilot screening programme for small molecule activators of p53
Berkson RG; Hollick JJ; Westwood NJ; Woods JA; Lane DP; Lain S
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2003;278(21):18720-18729
Oligomerization of the human ARF tumor suppressor and its response to oxidative stress
Menéndez S; Khan Z; Coomber DW; Lane DP; Higgins M; Koufali MM; Laín S
Article: BRITISH JOURNAL OF CANCER. 2003;88(4):636-643
Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein
Menéndez S; Higgins M; Berkson RG; Edling C; Lane DP; Laín S
Article: FEBS LETTERS. 2003;536(1-3):220-224
Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6
Camus S; Higgins M; Lane DP; Lain S
Article: ONCOGENE. 2001;20(36):4972-4983
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo
Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2001;276(22):19469-19482
Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser⁴³¹ by p90^RSK and cAMP-dependent protein kinase, but not its farnesylation at Cys⁴³³, is essential for LKB1 to suppress cell growth
Sapkota GP; Kieloch A; Lizcano JM; Lain S; Arthur JSC; Williams MR; Morrice N; Deak M; Alessi DR
Article: MOLECULAR CARCINOGENESIS. 2000;29(4):251-262
p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes
Paramio JM; Segrelles C; Laín S; Gómez-Casero E; Lane DP; Lane EB; Jorcano JL
Article: MOLECULAR AND CELLULAR BIOLOGY. 2000;20(22):8458-8467
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation
Rodriguez MS; Desterro JMP; Lain S; Lane DP; Hay RT
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2000;97(15):8501-8506
Activation of p53 in cervical carcinoma cells by small molecules
Hietanen S; Lain S; Krausz E; Blattner C; Lane DP
Article: ONCOGENE. 1999;18(51):7378-7386
Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B
Smart P; Lane EB; Lane DP; Midgley C; Vojtesek B; Laín S
Article: EMBO JOURNAL. 1999;18(22):6455-6461
SUMO-1 modification activates the transcriptional response of p53
Rodriguez MS; Desterro JMP; Lain S; Midgley CA; Lane DP; Hay RT
Article: EXPERIMENTAL CELL RESEARCH. 1999;248(2):457-472
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs
Laín S; Midgley C; Sparks A; Lane EB; Lane DP
Article: ONCOGENE. 1998;17(8):949-957
Differential expression and functionally co-operative roles for the retinoblastoma family of proteins in epidermal differentiation
Paramio JM; Laín S; Segrelles C; Lane EB; Jorcano JL
Article: ONCOGENE. 1998;16(5):587-596
Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule
Fåhraeus R; Laín S; Ball KL; Lane DP
Article: CURRENT BIOLOGY. 1997;7(1):71-80
Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21(WAF1)
Ball KL; Lain S; Fahraeus R; Smythe C; Lane DP
Article: CURRENT BIOLOGY. 1996;6(1):84-91
Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16(CDKN2/INK4A)
Fahraeus R; Paramio JM; Ball KL; Lain S; Lane DP
Article: JOURNAL OF GENERAL VIROLOGY. 1995;76:2679-2692
PU BOX-BINDING TRANSCRIPTION FACTORS AND A POU DOMAIN PROTEIN COOPERATE IN THE EPSTEIN-BARR-VIRUS (EBV) NUCLEAR-ANTIGEN-2-INDUCED TRANSACTIVATION OF THE EBV LATENT-MEMBRANE-PROTEIN-1 PROMOTER
SJOBLOM A; JANSSON A; YANG WW; LAIN S; NILSSON T; RYMO L
Article: NUCLEIC ACIDS RESEARCH. 1995;23(8):1327-1332
RNA HELICASE ACTIVITY OF THE PLUM POX POTYVIRUS CL PROTEIN EXPRESSED IN ESCHERICHIA-COLI - MAPPING OF AN RNA-BINDING DOMAIN
FERNANDEZ A; LAIN S; GARCIA JA
Visa fler

Alla övriga publikationer

Corrigendum: NATURE COMMUNICATIONS. 2023;14(1):5019
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (vol 14, 5019, 2023)
Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Fernandez AP; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Faernegardh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Hakansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Lain S
Review: CANCER & METABOLISM. 2020;8(1):12
Modulating pyrimidine ribonucleotide levels for the treatment of cancer
Mollick T; Lain S
Review: JOURNAL OF MOLECULAR CELL BIOLOGY. 2019;11(3):245-254
Small molecule activators of the p53 response
Ladds MJGW; Lain S
Corrigendum: NATURE COMMUNICATIONS. 2018;9(1):2071
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Fernandez AP; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Farnegardh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Hakansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Lain S
Review: BRITISH JOURNAL OF CANCER. 2013;109(12):2954-2958
p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy
Rao B; Lain S; Thompson AM
Editorial comment: ONCOTARGET. 2011;2(4):274-276
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs
van Leeuwen IMM; Lain S
Editorial comment: SEMINARS IN CANCER BIOLOGY. 2010;20(1):1-2
Drug discovery in the p53 field
Lain S
Review: NATURE REVIEWS CANCER. 2009;9(12):862-873
Awakening guardian angels: drugging the p53 pathway
Brown CJ; Lain S; Verma CS; Fersht AR; Lane DP
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2009;102:171-195
Sirtuins and p53
van Leeuwen I; Lain S
Review: SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND. 2008;6(4):240-243
p53 as a therapeutic target
Staples OD; Steele RJC; Lain S
Other: CELL CYCLE. 2008;7(21):3290-3291
If p53 can't do it, ask p73
Lain S
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2006;4(12):75
Activation of p53 by small molecules from fish to man
Lane D; Lain S
Review: BRITISH JOURNAL OF CANCER. 2005;92(3):434-444
P53 abnormalities and outcomes in colorectal cancer: a systematic review
Munro AJ; Lain S; Lane DP
Review: EUROPEAN JOURNAL OF CANCER. 2003;39(8):1053-1060
Improving cancer therapy by non-genotoxic activation of p53
Lain S; Lane D
Published conference paper: BIOCHEMICAL SOCIETY TRANSACTIONS. 2003;31(2):482-485
Protecting p53 from degradation
Lain S
Review: TRENDS IN MOLECULAR MEDICINE. 2002;8(4):S38-S42
Therapeutic exploitation of the p53 pathway
Lane DP; Lain S
Review: EXPERIMENTAL CELL RESEARCH. 1999;253(2):315-324
Accumulating active p53 in the nucleus by inhibition of nuclear export:: A novel strategy to promote the p53 tumor suppressor function
Laín S; Xirodimas D; Lane DP

Anställningar

Professor, Institutionen för mikrobiologi, tumör- och cellbiologi, Karolinska Institutet, 2015-

Examina och utbildning

Docent, Tumörbiologi, Karolinska Institutet, 2012

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI